BiondVax Pharmaceuticals Ltd. (BVXV)

NASDAQ: BVXV · IEX Real-Time Price · USD
9.92
+0.12 (1.17%)
Dec 5, 2022 3:18 PM EST - Market closed
1.17%
Market Cap 18.48M
Revenue (ttm) n/a
Net Income (ttm) -8.22M
Shares Out 747.15M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,211
Open 9.85
Previous Close 9.8
Day's Range 9.61 - 9.92
52-Week Range 5.34 - 34.9
Beta 2.36
Analysts Buy
Price Target 96.90 (+877.2%)
Earnings Date Nov 29, 2022

About BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated... [Read more]

Industry Pharmaceuticals
Founded 2003
CEO Ron Babecoff
Employees 15
Stock Exchange NASDAQ
Ticker Symbol BVXV
Full Company Profile

Financial Performance

Financial numbers in ILS Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BVXV stock is "Buy." The 12-month stock price forecast is 96.9, which is an increase of 877.21% from the latest price.

Price Target
$96.9
(877.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update

JERUSALEM, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic...

5 days ago - GlobeNewsWire

BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco

JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunoth...

2 weeks ago - PRNewsWire

BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences

JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializ...

2 weeks ago - GlobeNewsWire

BiondVax Announces Plan to Implement ADS Ratio Change

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializ...

3 weeks ago - GlobeNewsWire

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products ...

1 month ago - PRNewsWire

BiondVax provides plan to address Nasdaq compliance

JERUSALEM , Nov. 2, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products ...

1 month ago - PRNewsWire

BiondVax to Present at LD Micro Investor Conference in Los Angeles

Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing inno...

1 month ago - Newsfile Corp

BiondVax to present at LD Micro Investor Conference in Los Angeles

JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products...

1 month ago - PRNewsWire

BiondVax announces financial plans to support its ongoing NanoAb pipeline development

JERUSALEM, Israel , Sept. 30, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

2 months ago - PRNewsWire

BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of inno...

JERUSALEM , Sept. 20, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

2 months ago - PRNewsWire

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference

JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

2 months ago - PRNewsWire

BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update

JERUSALEM , Aug. 25, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatmen...

3 months ago - PRNewsWire

BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with a...

JERUSALEM , Aug. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative biological medici...

3 months ago - PRNewsWire

BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development ...

PEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax's clinical development ...

5 months ago - PRNewsWire

BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update

JERUSALEM , June 1, 2022 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the ...

6 months ago - PRNewsWire

BiondVax to Present at H.C. Wainwright Global Investment Conference

JERUSALEM , May 19, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the pr...

6 months ago - PRNewsWire

BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies P...

JERUSALEM , May 12, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the pr...

6 months ago - PRNewsWire

BiondVax to Present at this week's Biomed Israel Conference

JERUSALEM  , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the pr...

6 months ago - PRNewsWire

BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

JERUSALEM, March 28, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the p...

Other symbols: GSK
8 months ago - PRNewsWire

Why Is BiondVax (BVXV) Stock Up Today?

BVXV stock is climbing today on news that BiondVax has struck a deal to pursue a range of antibody treatments. Here's what to know.

8 months ago - InvestorPlace

Here's Why Biondvax Pharmaceuticals Shares Are Rising

Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline...

8 months ago - Benzinga

Why Are BiondVax Pharma Shares Gaining Today?

BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV) has signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen (UMG), both in Germany, for strategic collaboration t...

8 months ago - Benzinga

BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody ...

JERUSALEM, March 24, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the p...

8 months ago - PRNewsWire

European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional T...

JERUSALEM , March 14, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that it had been negotiating with the European Investment Bank (the "EIB") terms of restructuring ...

8 months ago - PRNewsWire

BiondVax to Present at Aegis Virtual Conference

JERUSALEM, Feb. 22, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the pr...

9 months ago - PRNewsWire